Stimulation of the high responders and strategies to prevent ovarian hyperstimulation syndrome

Middle East Fertility Society Journal

Volumn 13, Issue 3, 2008, Pages 147-155

  Hubayter, Ziad Rafic ^a   Muasher, Suheil Jamil ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

High responder; In vitro fertilization; OHSS; Ovarian hyperstimulation syndrome

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; ETHINYLESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; LEUPRORELIN; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; TRIPTORELIN;

CELL COUNT; CRYOPRESERVATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FERTILIZATION IN VITRO; HUMAN; LOW DRUG DOSE; NIDATION; OOCYTE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; PREGNANCY OUTCOME; PREGNANCY RATE; REVIEW; RISK REDUCTION; TREATMENT RESPONSE;

EID: 70349477048     PISSN: 11105690     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. www.cdc.gov/art/art2005 (accessed 5/20/2008)
2. Damario MA, Davis OK, Rosenwaks Z. The role of maternal age in assisted reproductive technologies. Reprod Med Rev 1999; 7: 141-160.
3. Dor J, Schulman A, Levran D, Ben-Rafael, Rudak E, Mashiach S. The treatment of patients with polycystic ovary syndrome by in-vitro fertilization: a comparison of results with those patients with tubal infertility. Hum Reprod 1990, 5: 816-8.
4. Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist / HMG superovulation for in vitro fertilization. Hum Reprod 1990; 5: 933-7.
5. Simon C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Remohi J, et al. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle- stimulating hormone step down regimen. Fertil Steril 1998; 70: 234-9.
6. Simon C, Cano F, Valbuena D, Remohi J, Pellicer A. Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod 1995; 10: 2432-7.
7. Pellicer A, Valbuena D, Cano F, Remohi J, Simon C. Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertil Steril 1996; 65: 1190-5.
8. Sharara F, McClamrock H. High estradiol levels and high oocyte yield are not detrimental to in-vitro fertilization outcome. Fertil Steril 1999; 72: 401-5.
9. Kligman I, Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil Steril 2001, 76: 1185-90.
10. Tomas C, Nuojua-Huttunen, Martikainen H. Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotropins in in-vitro fertilization. Hum Reprod 1997; 12: 220-3.
11. Danninger B, Brunner M, Obruca A, Feitchtinger W. Prediction of ovarian hyperstimulation syndrome of baseline ovarian volume prior to stimulation. Hum Reprod 1996; 11: 1597-9.
12. Chenette PE, Sauer MV, Paulson RJ. Very high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization. Fertil Steril 1990; 54: 858-63.
13. Chen QJ, Sun XX, Li L, Gao XH, Wu Y, Gemzell- Danielsson K, Cheng LN. Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH). Acta Obstet Gynecol Scand 2007; 86: 849-54.
14. Papageorgiou T, Guibert J, Goffinet F, Patrat C, Fulla Y, Janssens Y et al. Percentile curves of serum estradiol levels during controlled ovarian stimulation in 905 cycles stimulated with recombinant FSH show that high estradiol is not detrimental to IVF outcome. Hum Reprod 2002; 17: 2846-50.
15. Kok J, Looman C, Weima S, teVelde E. A high number of oocytes obtained after ovarian hyperstimulation for in- vitro fertilization or intracytoplasmic sperm injection is not associated with decreased pregnancy outcome. Fertil Steril 2006; 85: 918-24.
16. Damario MA, Barmat L, Liu H-C, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotropin releasing-hormone agonists improve in- vitro fertilization outcome in high responder patients. Hum Reprod 1997; 12: 2359-65.
17. Levinsohn-Tavor O, Friedler S, Schachter M, Raziel A, Strassburger D, Ron-El R. Coasting-what is the best formula? Hum Reprod 2003; 18: 937-40.
18. Waldenstrom U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by prolonged coasting of very hyperstimulated patients: A multicenter study. Hum Reprod 1999; 14: 294-7.
19. Ulug U, Ben-Shlomo I, Bahceci M. Predictors of success during the coasting period in high-responder patients undergoing controlled ovarian stimulation for assisted conception. Fertil Steril 2004; 82: 338-42.
20. Moreno JL. Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reprod Biomed Online 2004; 9: 500-4.
21. Mansour R, Aboulghar M, Serour G, Amin Y, Abou- Setta AM. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005; 20: 3167-72.
22. Schmidt DW, Maier DB, Nulsen J, Benadiva C. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in-vitro fertilization. Fertil Steril 2004; 82: 841-6.
23. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002; 17: 2787-94.
24. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001; 265: 175-82.
25. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005; 20: 2421-5.
26. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 2006; 21: 2830-7.
27. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84-91.
28. Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989; 52: 398-400.
29. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after co- treatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in-vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709-15.
30. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: A prospective randomized study. Hum Reprod 2005; 20: 1213-20. (Pubitemid 40796107)
31. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20: 2887-92.
32. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21: 1260-5.
33. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin- releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006; 86: 1682-7.
34. Weigert M, Krischker U, Pohl M, Poschalko G, Kindermann C, Feichtinger W. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: A prospective, randomized study. Fertil Steril 2002; 78: 34 9.
35. Williams SC, Gibbons WE, Muasher SJ, Oehninger S. Minimal ovarian hyperstimulation for in-vitro fertilization using sequential clomiphene citrate with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril 2002; 78: 1068-72.
36. Engel J, Ludwig M, Felberbaum R, Albano C, Devroey P, Diedrich K. Use of cetrorelix in combination with clomiphene citrate and gonadotropins: a suitable approach to 'friendly IVF'. Hum Reprod 2002; 17: 2022-6.
37. Hwang JL, Huang LW, Hsieh BC, Tsai YL, Huang SC, Chen CY, et al. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod 2003; 18: 45-9.
38. Jurema M, Nogueira D. In-vitro maturation of human oocytes for assisted reproduction. Fertil Steril 2006; 86: 1277-91
39. Cha KY, Han SY, Chung HM, Choi DH, Lim JM, Lee WS, et al. Pregnancies and deliveries after in-vitro maturation culture followed by in-vitro fertilization and embryo transfer without stimulation in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 978 3.
40. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective randomized study of human chorionic gonadotropin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod 2000; 15: 165-70.
41. Mikkelsen AL, Lindenberg S. Benefit of FSH priming of women with PCOS to the in-vitro maturation procedure and outcome: A randomized prospective study. Reproduction 2001; 122: 587-92.
42. Soderstrom-Anttila V, Makinen S, Tuuri T, Suikkari AM. Favorable pregnancy results with insemination of in-vitro matured oocytes from unstimulated patients. Hum Reprod 2005; 20: 1534-40
43. Cha KY, Chung HM, Lee DR, Kwon H, Chung MK, Park LS, et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in-vitro maturation and in-vitro fertilization-embryo transfer. Fertil Steril 2005; 83: 1461-5.
44. Child TJ, Abdul-Jalil AK, Gulekli B, Tan SL. In-vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril 2001; 76: 936 42.
45. Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan S. A comparison of in-vitro maturation and in-vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002; 100: 665-70.
46. Lin YH, Hwang JL, Huang LW, Mu SC, Seow KM, Chung J, et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod 2003; 18: 1632-6.
47. LeDu A, Kadoch IJ, Bourcigaux N, Doumerc S, Bourrier MC, Chevalier N, et al. In-vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: The French experience. Hum Reprod 2005; 20: 420-4.